Clinical Trials

OPEN for recruitment

ACCENT (AMP945-PC-201)

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Focal adhesion kinase (FAK) inhibitor AMP945 (oral) given prior to dosing with nab-paclitaxel and gemcitabine in first-line setting.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

AMG193 20210023

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination with Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

Diagnosis: Locally advanced (Stage III) unresectable or metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: PRMT5 inhibitor AMG193 (oral) monotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

AMG193 20230223

A Study Evaluating AMG 193 in Combination with Other Therapies in Participants with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: PRMT5 inhibitor AMG193 (oral) in combination with chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

DINE-PC

Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC).

Diagnosis: Pancreatic cancer.

Treatment: Dietetics counselling.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill), Epworth Geelong.

OPEN for recruitment

DIRECT-InspIRE Australia

Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy.

Diagnosis: Locally advanced (Stage III) unresectable pancreatic ductal adenocarcinoma.

Treatment: Irreversible Electroporation (IRE) with the NanoKnife system (surgical).

Epworth locations: Epworth Freemasons (East Melbourne).

OPEN for recruitment

NeoFOL-R

Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre prospective randomized, controlled trial (NeoFOL-R).

Diagnosis: Resectable pancreatic ductal adenocarcinoma.

Treatment: Surgery with mFOLFIRINOX chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

SPEAR

A Phase 2, Open-Label, Single-Arm Sulfasalazine Monotherapy Trial of Progression-Free Survival In Patients with Pancreatic Adenocarcinoma.

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Sulfasalazine monotherapy (oral).

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne).

OPEN for recruitment

SuperQoL

Supplemental Jejunal feeding to Improve Quality of Life (SuperQoL).

Diagnosis: Locally advanced (Stage III) unresectable or metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Dietetics counselling.

Epworth locations: Epworth Richmond.

OPEN for recruitment

TRIPP-FFX

An open-label, multi-centre, randomized study of Targeted Radioactive Intratumoural Placement of Phosphorous-32 (OncoSil™) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX chemotherapy alone in patients with unresectable locally advanced pancreatic adenocarcinoma.

Diagnosis: Locally advanced (Stage III) unresectable pancreatic ductal adenocarcinoma.

Treatment: P32 Oncosil (brachytherapy device) in combination with mFOLFIRINOX chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

ASCEND

A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

MK9999

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: TROP2 inhibitor MK-2870 monotherapy or in combination with chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

YH003004

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/ metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: YH003 (recombinant humanized agonistic CD40 IgG2 mAb) in combination with Toripalimab (anti-PD-1 mAb) with or without nab-paclitaxel + gemcitabine.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

Research Studies

OPEN for recruitment

APRISE

The Australian Pancreatic High-RIsk ScrEening (APRISE) Study 

Diagnosis or condition: Individuals considered at high-risk of developing pancreatic cancer. 

Epworth locations: Epworth Richmond.

OPEN for recruitment

MoST

Molecular Screening and Therapeutics Program (MoST)

Diagnosis or condition: Pancreatic cancer. 

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

OSCILLATE

An Observational Study following Circulating tumour DNA during multi-Agent Therapy in PDAC (OSCILLATE)

Diagnosis or condition: Unresectable pancreatic cancer.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

SCANPatient

Synoptic reporting of CT scans assessing cancer of the pancreas 

Diagnosis or condition: Suspected diagnosis of pancreatic cancer. 

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne).

OPEN for recruitment

PaCaSo

The Australian and Aotearoa New Zealand Pancreatic Cancer Surgical Outcomes (PaCaSO) Registry

Diagnosis or condition: Individuals who have experience of pancreatic cancer surgery, as a patient, carer, or loved one.

Epworth locations: Epworth Richmond.

OPEN for recruitment

PCB

Pancreaticobiliary Cancer Biobank (PCB)

Diagnosis or condition: Suspected diagnosis of pancreatic cancer or cholangiocarcinoma. 

Epworth locations: Epworth Richmond.